# 20/20 Biolabs, Inc.: financial statements, quarterly

AIDX · Nasdaq · CIK 1139685 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/aidx.md) · [Financials](/companies/aidx/financials.md) · [Filings](/companies/aidx/filings.md) · [Insiders](/companies/aidx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/aidx/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Revenue | $k | [554](/filings/0001213900-26-059542.md) | [535](/filings/0001213900-26-090042.md) | [353](/filings/0001213900-26-059542.md) | [731](/filings/0001213900-26-090042.md) |
| Cost of revenue | $k | [388](/filings/0001213900-26-059542.md) | [372](/filings/0001213900-26-090042.md) | [290](/filings/0001213900-26-059542.md) | [426](/filings/0001213900-26-090042.md) |
| Gross profit | $k | [166](/filings/0001213900-26-059542.md) | [163](/filings/0001213900-26-090042.md) | [62.9](/filings/0001213900-26-059542.md) | [305](/filings/0001213900-26-090042.md) |
| Research and development | $k | [137](/filings/0001213900-26-059542.md) | [194](/filings/0001213900-26-090042.md) | [153](/filings/0001213900-26-059542.md) | [258](/filings/0001213900-26-090042.md) |
| Selling, general and administrative | $k | [801](/filings/0001213900-26-059542.md) | [815](/filings/0001213900-26-090042.md) | [1,353](/filings/0001213900-26-059542.md) | [1,291](/filings/0001213900-26-090042.md) |
| Operating income | $k | [(772)](/filings/0001213900-26-059542.md) | [(846)](/filings/0001213900-26-090042.md) | [(1,443)](/filings/0001213900-26-059542.md) | [(1,244)](/filings/0001213900-26-090042.md) |
| Interest expense | $k | [0.7](/filings/0001213900-26-059542.md) | [0.9](/filings/0001213900-26-090042.md) | [267](/filings/0001213900-26-059542.md) | [272](/filings/0001213900-26-090042.md) |
| Net income | $k | [(765)](/filings/0001213900-26-090042.md) | [(841)](/filings/0001213900-26-090042.md) | [(2,175)](/filings/0001213900-26-090042.md) | [(1,506)](/filings/0001213900-26-090042.md) |
| Diluted EPS | $ per share | [(0.16)](/filings/0001213900-26-059542.md) | [(0.17)](/filings/0001213900-26-090042.md) | [(0.28)](/filings/0001213900-26-059542.md) | [(0.26)](/filings/0001213900-26-090042.md) |
| Basic EPS | $ per share | [(0.16)](/filings/0001213900-26-059542.md) | [(0.17)](/filings/0001213900-26-090042.md) | [(0.28)](/filings/0001213900-26-059542.md) | [(0.26)](/filings/0001213900-26-090042.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2023-12-31) | period not labelled (2024-12-31) | period not labelled (2025-03-31) | period not labelled (2025-06-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $k | not reported | [1,784](/filings/0001213900-26-037667.md) | not reported | not reported | [1,026](/filings/0001213900-26-090042.md) | [4,219](/filings/0001213900-26-059542.md) | [4,546](/filings/0001213900-26-090042.md) |
| Current assets | $k | not reported | [2,034](/filings/0001213900-26-037667.md) | not reported | not reported | [1,471](/filings/0001213900-26-090042.md) | [4,700](/filings/0001213900-26-059542.md) | [5,076](/filings/0001213900-26-090042.md) |
| Total assets | $k | not reported | [3,584](/filings/0001213900-26-037667.md) | not reported | not reported | [4,137](/filings/0001213900-26-090042.md) | [5,803](/filings/0001213900-26-059542.md) | [6,123](/filings/0001213900-26-090042.md) |
| Current liabilities | $k | not reported | [1,355](/filings/0001213900-26-037667.md) | not reported | not reported | [2,463](/filings/0001213900-26-090042.md) | [2,580](/filings/0001213900-26-059542.md) | [2,551](/filings/0001213900-26-090042.md) |
| Total liabilities | $k | not reported | [2,079](/filings/0001213900-26-037667.md) | not reported | not reported | [4,157](/filings/0001213900-26-090042.md) | [3,046](/filings/0001213900-26-059542.md) | [2,964](/filings/0001213900-26-090042.md) |
| Shareholders' equity | $k | [4,287](/filings/0001213900-26-037667.md) | [1,505](/filings/0001213900-26-090042.md) | [1,063](/filings/0001213900-26-090042.md) | [352](/filings/0001213900-26-090042.md) | [(19.2)](/filings/0001213900-26-090042.md) | [2,553](/filings/0001213900-26-090042.md) | [1,621](/filings/0001213900-26-090042.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(488)](/filings/0001213900-26-059542.md) | [(534) d](/filings/0001213900-26-090042.md) | [(1,289)](/filings/0001213900-26-059542.md) | [(605) d](/filings/0001213900-26-090042.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities

## Shares

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [4.8](/filings/0001213900-26-059542.md) | [4.8](/filings/0001213900-26-090042.md) | [7.7](/filings/0001213900-26-059542.md) | [10.8](/filings/0001213900-26-090042.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 12,770,303 at 2026-08-14, from the cover of the [10-Q filed 2026-08-14](/filings/0001213900-26-090042.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:51 ET. No prices; not investment advice.